Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multicenter study of MesenCure for pulmonary manifestations of COVID-19
MOH_2021-01-14_009666Phase 2Active, not recruiting
- Sponsor
- Bonus Therapeutics
- Start
- Jan 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of MesenCure in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Bonus Therapeutics. Primary endpoints: Safety and Efficacy. Started Jan 2021; status: active, not recruiting.
02
Drugs
MesenCure
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2021-01-14_009666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-14_009666.